Episode Details

Back to Episodes
Episode 143: #JPM21: Déjà vu in Alzheimer's research, and OWS's legacy

Episode 143: #JPM21: Déjà vu in Alzheimer's research, and OWS's legacy

Published 5 years, 9 months ago
Description
We're devoting this episode to the news coming out of the just-concluded J.P. Morgan Healthcare Conference, the drug industry's largest annual meeting. First, we'll dissect Eli Lilly's surprising data on a new Alzheimer's disease treatment and dig into its implications for the field. Then, we discuss whether there's a bubble inflating in the genome editing world, debate who will run the FDA under a President Biden, and consider the legacy of Moncef Slaoui, the outgoing leader of Operation Warp Speed.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us